GASTROENTEROLOGY · PHASE III
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study
In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis (tissue scarring), suggesting continued improvement in liver health. These data warrant the continued investigation of pemvidutide in a Phase 3 trial.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
1 min readThe Lancet Gastroenterology & Hepatology